Search results for "Protection"

showing 10 items of 1623 documents

CT exposure in adult and paediatric patients: a review of the mechanisms of damage, relative dose and consequent possible risks.

2014

An increase has been observed not only in the absolute number of CT examinations but also in the length of coverage and number of scanning phases, with the result that exposure to ionising radiation from CT is becoming an increasingly serious problem. The extent of the problem is not entirely known and cannot be adequately addressed without proper knowledge of all the phases that leads to the effective dose calculation. In light of the growing awareness of the issue of ionising radiation dose and the possible risk for the individual and the population, there is a need for radiologists, medical physicists and radiographers to play an active role in dose management. In this review, the author…

Adultmedicine.medical_specialtyPopulationGuidelines as TopicRadiation DosageEffective dose (radiation)PediatricsRisk AssessmentCaliforniaRadiation ProtectionRisk FactorsNeoplasmsRadiation Ionizingmedicinemedia_common.cataloged_instanceHumansRadiology Nuclear Medicine and imagingMedical physicsEuropean UnionEuropean unioneducationChildMathematical ComputingNeuroradiologymedia_commoneducation.field_of_studyEvidence-Based Medicinemedicine.diagnostic_testbusiness.industryCT Radiation exposure DLP CTDI Radiation dose Absorbed doseInterventional radiologyGeneral MedicineEvidence-based medicineAbsorbed doseRadiologyRisk assessmentbusinessRadiologyTomography X-Ray ComputedLa Radiologia medica
researchProduct

Fetal dose measurements and shielding efficiency assessment in a custom setup of (192)Ir brachytherapy for a pregnant woman with breast cancer.

2015

To assess the radiation dose to the fetus of a pregnant patient undergoing high-dose-rate (HDR) (192)Ir interstitial breast brachytherapy, and to design a new patient setup and lead shielding technique that minimizes the fetal dose.Radiochromic films were placed between the slices of an anthropomorphic phantom modeling the patient. The pregnant woman was seated in a chair with the breast over a table and inside a leaded box. Dose variation as a function of distance from the implant volume as well as dose homogeneity within a representative slice of the fetal position was evaluated without and with shielding.With shielding, the peripheral dose after a complete treatment ranged from 50 cGy at…

Adultmedicine.medical_specialtymedicine.medical_treatmentBrachytherapyBrachytherapyBiophysicsGeneral Physics and AstronomyFetal positionBreast NeoplasmsIonizing radiationLead shieldingBreast cancerFetusRadiation ProtectionPregnancymedicineHumansRadiology Nuclear Medicine and imagingRadiometrybusiness.industryRadiotherapy Planning Computer-AssistedRadiotherapy DosageGeneral Medicinemedicine.diseaseIridium RadioisotopesSurgeryRadiation therapyPregnancy ComplicationsElectromagnetic shieldingFemaleImplantbusinessNuclear medicinePhysica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)
researchProduct

Aging and neuroinflammatory disorders: New biomarkers and therapeutic targets

2019

: Chronic neuroinflammation is a common feature of the pathogenic mechanisms involved in various neurodegenerative age-associated disorders, such as Alzheimer's disease, multiple sclerosis, Parkinson’s disease, and dementia. : In particular, persistent low-grade inflammation may disrupt the brain endothelial barrier and cause a significant increase of pro-inflammatory cytokines and immune cells into the cerebral tissue that, in turn, leads to microglia dysfunction and loss of neuroprotective properties. : Nowadays, growing evidence highlights a strong association between persistent peripheral inflammation, as well as metabolic alterations, and neurodegenerative disorder susceptibility. The…

AgingInflammationDiseaseNeurodegenerative diseaseNeuroprotection03 medical and health sciences0302 clinical medicineImmune systemDrug DiscoverymedicineDementiaHumansTherapeutic targetsNeuroinflammation030304 developmental biologyPharmacologyInflammation0303 health sciencesMicrogliabusiness.industryMultiple sclerosisNeurodegenerative DiseasesBiomarkermedicine.diseasemedicine.anatomical_structureMicrogliamedicine.symptombusinessNeuroscienceNeuroinflammatory030217 neurology & neurosurgeryBiomarkers
researchProduct

Neuroprotective effects of behavioural training and nicotine on age-related deficits in spatial learning.

2006

Studies in humans and animals show a clear decline in spatial memory with age and several approaches have been adopted to alleviate this impairment. The purpose of our review is to assess the studies that have suggested the possible neuroprotective actions of behavioural training and nicotine-applied both independently and in conjunction-on age-related deficits in spatial learning. Both spatial pretraining and nonspatial experiences influence an animal's performance in spatial tasks. In aged rats, the experience of training in the water maze task increases the number of newly generated neurons in the hippocampus. The neuroprotective effects of nicotine have been demonstrated in both in-vitr…

AgingNicotineHippocampusWater mazeReceptors NicotinicNeuroprotectionSpatial memoryHippocampusNicotineBehavior TherapyEscape ReactionOrientationmedicineAnimalsHumansMaze LearningProblem SolvingPharmacologyConfoundingNeurodegenerative DiseasesSpatial cognitionRatsPsychiatry and Mental healthNeuroprotective AgentsPractice PsychologicalMental RecallSpatial learningSeptum PellucidumPsychologyCognitive psychologymedicine.drugBehavioural pharmacology
researchProduct

Pharmacological intervention in age-associated brain disorders by Flupirtine: Alzheimer’s and Prion diseases

1998

Alzheimer's disease, a major form of dementia in the elderly has become an increasingly important health problem in developed countries. In vitro studies on primary neurons demonstrate that Flupirtine (Katadolon) at a concentration of 1 microg/ml, significantly reduces the neurotoxic (apoptotic) effect displayed by A beta25-35, a segment of the amyloid beta-protein precursor the etiologic agent of Alzheimer's disease. Flupirtine, which has been in clinical use since 10 years ago, prevents the toxic effect of PrP, the presumed etiologic agent of the Creutzfeldt-Jakob disease as well as the excitatory amino acid glutamate on cortical neurons. Flupirtine displays a bimodal activity. Its strong…

AgingTime FactorsCell SurvivalPrionsMolecular Sequence DataAminopyridinesApoptosisPharmacologyBiologyNeuroprotectionPrion Diseaseschemistry.chemical_compoundGlutamatesAlzheimer DiseasemedicineAnimalsAmino Acid SequenceRats WistarCells CulturedNeuronsAmyloid beta-PeptidesGlutamate receptorNeurotoxicityBiological activityGlutathionemedicine.diseasePeptide FragmentsRatsNeuroprotective Agentsmedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2BiochemistrychemistryCalciumNeuronAlzheimer's diseaseFlupirtineDevelopmental Biologymedicine.drugMechanisms of Ageing and Development
researchProduct

Principles and requirements for stroke recovery science

2020

The disappointing results in bench-to-bedside translation of neuroprotective strategies caused a certain shift in stroke research towards enhancing the endogenous recovery potential of the brain. One reason for this focus on recovery is the much wider time window for therapeutic interventions which is open for at least several months. Since recently two large clinical studies using d-amphetamine or fluoxetine, respectively, to enhance post-stroke neurological outcome failed again it is a good time for a critical reflection on principles and requirements for stroke recovery science. In principal, stroke recovery science deals with all events from the molecular up to the functional and behav…

Agingmedicine.medical_specialtyCombination therapymedicine.medical_treatmenttranslationNeuroprotectioncombination therapyrecovery03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationchronic strokeHumansMedicineReview ArticlesChronic strokeStroke030304 developmental biologyNeurotransmitter Agents0303 health sciencesbusiness.industryRegeneration (biology)BrainRecovery of Functionmedicine.diseaseStrokeMatrix Metalloproteinase 9NeurologyTissue Plasminogen ActivatorregenerationIntercellular Signaling Peptides and ProteinsNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessStroke recovery030217 neurology & neurosurgeryJournal of Cerebral Blood Flow & Metabolism
researchProduct

The emerging role of miRNA-132/212 cluster in neurologic and cardiovascular diseases: Neuroprotective role in cells with prolonged longevity

2021

Abstract miRNA-132/212 are small regulators of gene expression with a function that fulfills a vital function in diverse biological processes including neuroprotection of cells with prolonged longevity in neurons and the cardiovascular system. In neurons, miRNA-132 appears to be essential for controlling differentiation, development, and neural functioning. Indeed, it also universally promotes axon evolution, nervous migration, plasticity as well, it is suggested to be neuroprotective against neurodegenerative diseases. Moreover, miRNA-132/212 disorder leads to neural developmental perturbation, and the development of degenerative disorders covering Alzheimer’s, Parkinson’s, and epilepsy’s …

Agingmedicine.medical_specialtyNeurologyDegenerative Disordermedia_common.quotation_subjectNeuroprotection03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmicroRNAAnimalsHumansMedicineMyocytes CardiacMolecular Targeted TherapyAxonCellular SenescenceComputingMilieux_MISCELLANEOUS030304 developmental biologymedia_commonNeurons0303 health sciencesbusiness.industryNeurodegenerationAutophagyLongevityNeurodegenerative Diseasesmedicine.diseaseNeuroprotection3. Good healthMicroRNAsmedicine.anatomical_structureGene Expression RegulationCardiovascular DiseasesbusinessNeuroscience030217 neurology & neurosurgeryDevelopmental Biology
researchProduct

Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid de…

2012

Alzheimer's disease (AD) is characterized by amyloid-beta deposition in amyloid plaques, neurofibrillary tangles, inflammation, neuronal loss, and cognitive deficits. Cannabinoids display neuromodulatory and neuroprotective effects and affect memory acquisition. Here, we studied the impact of cannabinoid receptor type 1 (CB1) deficiency on the development of AD pathology by breeding amyloid precursor protein (APP) Swedish mutant mice (APP23), an AD animal model, with CB1-deficient mice. In addition to the lower body weight of APP23/CB1(-/-) mice, most of these mice died at an age before typical AD-associated changes become apparent. The surviving mice showed a reduced amount of APP and its …

Agingmedicine.medical_specialtyPathologyCannabinoid receptormedicine.medical_treatmentMutantMice TransgenicInflammationDiseaseNeuroprotectionAmyloid beta-Protein PrecursorMiceReceptor Cannabinoid CB1Alzheimer DiseaseCell Line TumorInternal medicinemental disordersmedicineAmyloid precursor proteinAnimalsHumansMaze LearningCognitive impairmentAmyloid beta-Peptidesbiologybusiness.industryGeneral NeuroscienceBody WeightAge FactorsBrainPeptide FragmentsDisease Models AnimalEndocrinologyGene Expression RegulationMutationbiology.proteinlipids (amino acids peptides and proteins)MicrogliaNeurology (clinical)CannabinoidGeriatrics and Gerontologymedicine.symptomCognition DisordersbusinessDevelopmental BiologyNeurobiology of Aging
researchProduct

Cannabinoid and nitric oxide signaling interplay in the modulation of hippocampal hyperexcitability: study on electrophysiological and behavioral mod…

2015

A growing bulk of evidence suggests that cannabinoid system plays a pivotal role in the control of hyperexcitability phenomena. Notwithstanding, the anticonvulsant action of cannabinoids has not been fully addressed, in particular the involvement of potential cellular neuromodulators, for instance nitric oxide. In the current study, we focused on two distinct rat models of temporal lobe epilepsy, the Maximal Dentate Activation and the pilocarpine-induced acute seizures, providing both electrophysiological and behavioral data on cannabinoid and nitrergic system interplay. We evaluated the antiepileptic effects of WIN 55,212-2, (R)-(+)-[2,3-dihydro-5-methyl-3-(4- morpholinylmethyl) pyrrolo[1,…

AgonistAM251MaleCannabinoid receptorIndazolesmedicine.drug_classmedicine.medical_treatmentMorpholinesHippocampusPharmacologyNaphthalenesNitric OxideHippocampusSettore BIO/09 - FisiologiaEpilepsyPiperidinesReceptor Cannabinoid CB1medicineAnimalshippocampus temporal lobe epilepsy cannabinoids behavior percentage of protection electrophysiology.Rats WistarWIN 55212-2Cannabinoid Receptor AgonistsDose-Response Relationship DrugCannabinoidsGeneral NeurosciencePilocarpinemedicine.diseaseEndocannabinoid systemBenzoxazinesRatsDisease Models AnimalEpilepsy Temporal LobePyrazolesCannabinoidNitric Oxide SynthasePsychologyNeurosciencemedicine.drug
researchProduct

Fingolimod as a Treatment in Neurologic Disorders Beyond Multiple Sclerosis

2020

Abstract Fingolimod is an approved treatment for relapsing–remitting multiple sclerosis (MS), and its properties in different pathways have raised interest in therapy research for other neurodegenerative diseases. Fingolimod is an agonist of sphingosine-1-phosphate (S1P) receptors. Its main pharmacologic effect is immunomodulation by lymphocyte homing, thereby reducing the numbers of T and B cells in circulation. Because of the ubiquitous expression of S1P receptors, other effects have also been described. Here, we review preclinical experiments evaluating the effects of treatment with fingolimod in neurodegenerative diseases other than MS, such as Alzheimer’s disease or epilepsy. Fingolimo…

AgonistSphingosine 1 Phosphate Receptor ModulatorsMultiple Sclerosismedicine.drug_classDrug Evaluation PreclinicalDiseaseReview ArticleRM1-950PharmacologyNeuroprotection03 medical and health sciencesEpilepsyMice0302 clinical medicineNeurotrophic factorsAlzheimer DiseasemedicineAnimalsHumansLymphocytes030304 developmental biologyPharmacology0303 health sciencesEpilepsyMicrogliabusiness.industryFingolimod HydrochlorideMultiple sclerosisAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseFingolimod3. Good healthRatsDisease Models Animalmedicine.anatomical_structureNeuroprotective AgentsTherapeutics. PharmacologyNervous System Diseasesbusiness030217 neurology & neurosurgerymedicine.drugDrugs in R&D
researchProduct